vs
Amalgamated Financial Corp.（AMAL）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Amalgamated Financial Corp.的1.5倍（$127.1M vs $85.2M），再鼎医药同比增速更快（17.1% vs 9.4%），Amalgamated Financial Corp.自由现金流更多（$134.4M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 4.3%）
CI金融集团是一家总部位于加拿大安大略省多伦多的投资管理公司，面向高净值个人投资者提供投资管理与财富管理服务，同时也为投资组合经理及机构投资者提供经纪与交易服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
AMAL vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.5倍
$85.2M
营收增速更快
ZLAB
高出7.7%
9.4%
自由现金流更多
AMAL
多$161.1M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
4.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $85.2M | $127.1M |
| 净利润 | — | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 39.0% | -54.6% |
| 净利率 | — | — |
| 营收同比 | 9.4% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.88 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMALZLAB
| Q4 25 | $85.2M | $127.1M | ||
| Q3 25 | $85.6M | $115.4M | ||
| Q2 25 | $80.9M | $109.1M | ||
| Q1 25 | $77.0M | $105.7M | ||
| Q4 24 | $77.9M | $108.5M | ||
| Q3 24 | $81.0M | $101.8M | ||
| Q2 24 | $78.5M | $100.1M | ||
| Q1 24 | $78.3M | $87.1M |
净利润AMALZLAB
| Q4 25 | — | — | ||
| Q3 25 | $26.8M | $-36.0M | ||
| Q2 25 | $26.0M | $-40.7M | ||
| Q1 25 | $25.0M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $27.9M | $-41.7M | ||
| Q2 24 | $26.8M | $-80.3M | ||
| Q1 24 | $27.2M | $-53.5M |
毛利率AMALZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率AMALZLAB
| Q4 25 | 39.0% | -54.6% | ||
| Q3 25 | 42.9% | -42.3% | ||
| Q2 25 | 43.8% | -50.3% | ||
| Q1 25 | 45.1% | -53.3% | ||
| Q4 24 | 42.4% | -62.6% | ||
| Q3 24 | 47.2% | -66.6% | ||
| Q2 24 | 45.6% | -76.0% | ||
| Q1 24 | 49.2% | -80.7% |
净利率AMALZLAB
| Q4 25 | — | — | ||
| Q3 25 | 31.3% | -31.2% | ||
| Q2 25 | 32.1% | -37.3% | ||
| Q1 25 | 32.5% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 34.5% | -40.9% | ||
| Q2 24 | 34.1% | -80.2% | ||
| Q1 24 | 34.8% | -61.4% |
每股收益（稀释后）AMALZLAB
| Q4 25 | $0.88 | $-0.05 | ||
| Q3 25 | $0.88 | $-0.03 | ||
| Q2 25 | $0.84 | $-0.04 | ||
| Q1 25 | $0.81 | $-0.04 | ||
| Q4 24 | $0.78 | $-0.09 | ||
| Q3 24 | $0.90 | $-0.04 | ||
| Q2 24 | $0.87 | $-0.08 | ||
| Q1 24 | $0.89 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $291.2M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $794.5M | $715.5M |
| 总资产 | $8.9B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMALZLAB
| Q4 25 | $291.2M | $689.6M | ||
| Q3 25 | $115.5M | $717.2M | ||
| Q2 25 | $171.1M | $732.2M | ||
| Q1 25 | $65.7M | $757.3M | ||
| Q4 24 | $60.7M | $779.7M | ||
| Q3 24 | $149.2M | $616.1M | ||
| Q2 24 | $58.0M | $630.0M | ||
| Q1 24 | $155.2M | $650.8M |
股东权益AMALZLAB
| Q4 25 | $794.5M | $715.5M | ||
| Q3 25 | $775.6M | $759.9M | ||
| Q2 25 | $754.0M | $791.7M | ||
| Q1 25 | $736.0M | $810.8M | ||
| Q4 24 | $707.7M | $840.9M | ||
| Q3 24 | $698.2M | $667.7M | ||
| Q2 24 | $646.0M | $704.2M | ||
| Q1 24 | $616.8M | $762.2M |
总资产AMALZLAB
| Q4 25 | $8.9B | $1.2B | ||
| Q3 25 | $8.7B | $1.2B | ||
| Q2 25 | $8.6B | $1.2B | ||
| Q1 25 | $8.3B | $1.2B | ||
| Q4 24 | $8.3B | $1.2B | ||
| Q3 24 | $8.4B | $985.3M | ||
| Q2 24 | $8.3B | $987.4M | ||
| Q1 24 | $8.1B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $135.8M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $134.4M | $-26.7M |
| 自由现金流率自由现金流/营收 | 157.8% | -21.0% |
| 资本支出强度资本支出/营收 | 1.6% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $229.4M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流AMALZLAB
| Q4 25 | $135.8M | $-26.0M | ||
| Q3 25 | $39.5M | $-32.0M | ||
| Q2 25 | $24.9M | $-31.0M | ||
| Q1 25 | $34.2M | $-61.7M | ||
| Q4 24 | $124.1M | $-55.8M | ||
| Q3 24 | $35.8M | $-26.8M | ||
| Q2 24 | $28.0M | $-42.2M | ||
| Q1 24 | $31.3M | $-90.1M |
自由现金流AMALZLAB
| Q4 25 | $134.4M | $-26.7M | ||
| Q3 25 | $38.3M | $-35.0M | ||
| Q2 25 | $24.2M | $-33.9M | ||
| Q1 25 | $32.5M | $-63.2M | ||
| Q4 24 | $122.3M | $-58.4M | ||
| Q3 24 | $35.2M | $-28.2M | ||
| Q2 24 | $27.8M | $-42.9M | ||
| Q1 24 | $31.1M | $-91.1M |
自由现金流率AMALZLAB
| Q4 25 | 157.8% | -21.0% | ||
| Q3 25 | 44.7% | -30.4% | ||
| Q2 25 | 29.9% | -31.1% | ||
| Q1 25 | 42.2% | -59.9% | ||
| Q4 24 | 157.0% | -53.8% | ||
| Q3 24 | 43.4% | -27.7% | ||
| Q2 24 | 35.4% | -42.9% | ||
| Q1 24 | 39.7% | -104.5% |
资本支出强度AMALZLAB
| Q4 25 | 1.6% | 0.5% | ||
| Q3 25 | 1.4% | 2.6% | ||
| Q2 25 | 0.9% | 2.6% | ||
| Q1 25 | 2.3% | 1.5% | ||
| Q4 24 | 2.3% | 2.4% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 0.3% | 0.7% | ||
| Q1 24 | 0.3% | 1.1% |
现金转化率AMALZLAB
| Q4 25 | — | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 0.96× | — | ||
| Q1 25 | 1.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 1.05× | — | ||
| Q1 24 | 1.15× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMAL
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
